1-11 of 11
Jorge E. Cortes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval

Open Access
Clinical Trials & Observations
Kellen Cristine Tjioe, Marisol Miranda-Galvis, Kenza Mamouni, Thalyta Freitas, Muhannad Sharara, Brenda Santellano, Claudia Guillén-Lopez, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2025) 9 (15): 3810–3813.
https://doi.org/10.1182/bloodadvances.2024014340
Published: 2025
Includes: Supplemental data
Journal Articles

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

Open Access
Clinical Trials & Observations
Jorge E. Cortes, Jay Yang, Gail J Roboz, Shira Naomi Dinner, Eunice S. Wang, Andrew H Wei, Hua Tian, Francois di Trapani, Maria R Baer, William B Donnellan, Justin M Watts
Journal: Blood Advances
Blood Adv bloodadvances.2025016718.
https://doi.org/10.1182/bloodadvances.2025016718
Published: 2025
Includes: Supplemental data
Journal Articles

Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review

Free
Marisol Miranda-Galvis, Kellen C. Tjioe, E. Andrew Balas, Gagan Agrawal, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6466–6491.
https://doi.org/10.1182/bloodadvances.2023010690
Published: 2023
Includes: Supplemental data
Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Free
Clinical Trials & Observations
Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1719–1728.
https://doi.org/10.1182/bloodadvances.2020003510
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Free
Clinical Trials & Observations
Je-Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D. Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2032–2043.
https://doi.org/10.1182/bloodadvances.2019000757
Published: 2020
Includes: Supplemental data
Journal Articles

Clinical value of event-free survival in acute myeloid leukemia

Free
Clinical Trials & Observations
Abhishek Maiti, Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia-Manero, Marina Y. Konopleva, Courtney D. DiNardo, Srdan Verstovsek, Michael Andreeff, Tapan M. Kadia, Helen O. Ajufo, Rohit V. Goswamy, Carlos Blanco, Miguel Velasquez, Naval G. Daver, Naveen Pemmaraju, Sherry R. Pierce, William G. Wierda, Steven M. Kornblau, Farhad Ravandi, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1690–1699.
https://doi.org/10.1182/bloodadvances.2019001150
Published: 2020
Includes: Supplemental data
Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Free
Clinical Trials & Observations
Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2019) 3 (6): 851–861.
https://doi.org/10.1182/bloodadvances.2018025874
Published: 2019
Includes: Supplemental data
Journal Articles

A second-generation TKI should always be used as initial therapy for CML

Free
Clinical Trials & Observations
Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3653–3655.
https://doi.org/10.1182/bloodadvances.2018018655
Published: 2018
Journal Articles

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy

Free
Clinical Trials & Observations
Zimu Gong, L. Jeffrey Medeiros, Jorge E. Cortes, Zi Chen, Lan Zheng, Yan Li, Shi Bai, Pei Lin, Roberto N. Miranda, Jeffrey L. Jorgensen, Timothy J. McDonnell, Wei Wang, Hagop M. Kantarjian, Shimin Hu
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2541–2552.
https://doi.org/10.1182/bloodadvances.2017011858
Published: 2017
Includes: Supplemental data
Journal Articles

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Free
Clinical Trials & Observations
Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Naval Daver, Courtney D. DiNardo, Christopher B. Benton, Koichi Takahashi, Zeev Estrov, Sherry R. Pierce, Michael Andreeff, Jorge E. Cortes, Tapan M. Kadia
Journal: Blood Advances
Blood Adv (2017) 1 (17): 1312–1323.
https://doi.org/10.1182/bloodadvances.2017008227
Published: 2017
Includes: Supplemental data
Journal Articles

Therapy-related myelofibrosis does not appear to exist

Free
Clinical Trials & Observations
Lucia Masarova, Gabriele Todisco, Taghi Manshouri, Kate J. Newberry, Jorge E. Cortes, Hagop M. Kantarjian, Zeev Estrov, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2017) 1 (14): 863–866.
https://doi.org/10.1182/bloodadvances.2017007369
Published: 2017